ZNF20 Inhibitors
Chemical inhibitors of ZNF20 can modulate its activity by targeting the cell cycle and transcriptional regulation mechanisms. Palbociclib, Ribociclib, and Abemaciclib, as selective inhibitors of cyclin-dependent kinases CDK4 and CDK6, can halt cell cycle progression at the G1 phase. This arrest is achieved by preventing the phosphorylation of retinoblastoma (Rb) protein, a key regulator of cell cycle progression from G1 to S phase. In doing so, these inhibitors can manage the regulation of ZNF20 if it is implicated in the cell cycle. Alsterpaullone, on the other hand, extends its kinase inhibition to CDK1, CDK5, and GSK-3β, which are involved not only in cell cycle control but also in apoptosis pathways. Such broad kinase inhibition can alter the activity of ZNF20, particularly if ZNF20's function is intertwined with these cellular processes.
Roscovitine and Purvalanol A further expand the spectrum of CDK inhibition, targeting CDK1, CDK2, and CDK7, and in Purvalanol A's case, also CDK5 and CDK9. This can influence the activity of ZNF20 by disrupting the cell cycle and transcriptional regulation at multiple points. Similarly, Dinaciclib's robust inhibition of CDK1, CDK2, CDK5, and CDK9 can lead to widespread disruption of cellular processes, which in turn can affect the activity of ZNF20. Flavopiridol, by acting as a pan-CDK inhibitor, has the capacity to inhibit cell cycle progression and transcriptional regulation broadly, which may influence ZNF20's activity. SNS-032 and AZD5438, with their potent inhibition of CDK2, CDK7, and CDK9, and CDK1, CDK2, and CDK9 respectively, can interfere with the transcription and cell cycle regulation, thus managing the activity of ZNF20. Lastly, Seliciclib's inhibition of CDK2, CDK7, and CDK9 can lead to cell cycle arrest and transcriptional dysregulation, which can manage ZNF20's function if it is involved in these pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. ZNF20 activity can be inhibited by blocking the cell cycle progression at the G1 phase, which is regulated by CDK4/6 complexes. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib specifically inhibits CDK4/6, similar to Palbociclib, which can lead to inhibition of the downstream effects that control cell cycle progression, potentially inhibiting ZNF20 function related to cell proliferation. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Abemaciclib is another CDK4/6 inhibitor that can halt cell cycle progression, thereby inhibiting the activity of ZNF20 if it is involved in cell cycle regulation. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone inhibits cyclin-dependent kinases such as CDK1, CDK5, and GSK-3β. By inhibiting these kinases, it can interfere with cell cycle and apoptosis pathways, which may in turn inhibit ZNF20 function if it is involved in these processes. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Roscovitine targets CDKs, particularly CDK1, CDK2, and CDK7. Inhibition of these kinases can disrupt the cell cycle and transcriptional regulation, possibly inhibiting ZNF20's involvement in these cellular mechanisms. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $71.00 $291.00 | 4 | |
Purvalanol A is a potent inhibitor of CDKs, especially CDK1, CDK2, CDK5, and CDK9. Its inhibition of CDKs can affect cell cycle progression and transcriptional regulation, which may functionally inhibit ZNF20 if it plays a role in these pathways. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $242.00 $871.00 | 1 | |
Dinaciclib robustly inhibits CDKs, with a strong effect on CDK1, CDK2, CDK5, and CDK9. This broad CDK inhibition can disrupt various cellular processes, potentially leading to functional inhibition of ZNF20 if it is involved in those processes. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
Flavopiridol is a pan-CDK inhibitor that can inhibit cell cycle progression and transcriptional regulation, thereby potentially inhibiting the activity of ZNF20 if it interacts with these cellular mechanisms. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
SNS-032 is a potent and selective inhibitor of CDK2, CDK7, and CDK9. It affects transcription and cell cycle regulation, which could inhibit ZNF20 activity if the protein is involved in these pathways. | ||||||
AZD 5438 | 602306-29-6 | sc-361115 sc-361115A | 10 mg 50 mg | $205.00 $865.00 | ||
AZD5438 inhibits CDK1, CDK2, and CDK9, leading to cell cycle arrest and potential disruption of transcriptional regulation. This could inhibit ZNF20 if it plays a role in cell cycle control or transcription-related functions. | ||||||